The Filing Desk

AbbVie vs Pfizer

AbbVie ABBV · Pfizer PFE · Health Care

Pfizer reported revenue of $62.6 billion in fiscal 2025, about the same as AbbVie's $61.2 billion in fiscal 2025. AbbVie's revenue grew 8.6% in its latest year, and Pfizer's fell 1.6%. Free cash flow was $17.8 billion at AbbVie and $9.1 billion at Pfizer.

Side by side

AbbViePfizer
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$61.2B$62.6B
Revenue growth8.6%−1.6%
Revenue growth a year, last 5 years6.0%8.5%
Gross margin70.2%74.3%
Operating margin24.6%—
Net margin6.9%12.4%
Free cash flow$17.8B$9.1B
Free cash flow margin29.1%14.5%
Return on capital15.7%7.2%
Net debt to EBITDA2.7x3.2x
Dividends and buybacks$12.6B$9.8B
Change in diluted share count0.0%0.2%
Last close$283.54$27.54
P/E at the last close48.8×39.3×
Insider trades, last 12 monthssold $30.8 millionbought $3.0 million, sold $134,661
Piotroski F-score7 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AbbViePfizer
Operating margin
Percent of revenue
AbbViePfizer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbViePfizer

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbbVie and Pfizer pages.